← Leaderboards
Richard Allan Maki
Torrey Pines Pharmaceuticals, Inc.
$795,887
Attributed
$795,887
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $274.4K · FY2009–13$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$795,887 · 2
By mechanism
R43$795,887 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseChlorinationMouse ModelPeroxidasesResearch StudyHypochlorous AcidInflammatoryLeukocytesMacrophageOxidantsOxidationPeroxidationProteinsInhibitor/AntagonistEnzymesAstrocytesInfectionNeutrophilLeadAtherosclerosisLipidsNovel TherapeuticsSite
Grant awards (3)
Development of Myeloperoxidase Inhibitors to Treat Alzheimer's Disease$266,344
R43 · FY2013 · AG · contact PI
Development of Myeloperoxidase Inhibitors to Treat Alzheimer's Disease$255,109
R43 · FY2012 · AG · contact PI
Development of myeloperoxidase inhibitors to treat atherosclerosis$274,434
R43 · FY2009 · HL · contact PI